Our clinical and discovery pipeline programs are centered on restoring immune homeostasis in patients with severe inflammatory and autoimmune diseases.
Q32 Bio is evaluating bempikibart (ADX-914), an anti-IL-7Rα antibody inhibiting IL-7 and TSLP mediated signaling, in two Phase 2 clinical studies: SIGNAL-AD, a Phase 2 study in patients with atopic dermatitis [ADX-914-202] and SIGNAL-AA, a Phase 2 study in patients with alopecia areata [ADX-914-203]. Topline Phase 2 results are expected in 2H’24.
Q32 Bio has developed a novel discovery platform that is enabling the generation of first-in-class complement inhibitors that target diseased tissues. From this platform, a strong pipeline of promising candidates, with potential therapeutic activity across the numerous diseases in which C3 complement fragments are deposited in the diseased tissue, is being advanced through research and into clinical development.
In preclinical studies, our lead clinical candidate, ADX-097, distributed to affected tissues/organs and demonstrated durable tissue pharmacokinetics and pharmacodynamics. Based on the compelling evidence from these studies, ADX-097 may potently and durably block complement activity in humans, while preserving the body’s ability to fight infection effectively, thereby avoiding the potentially damaging effects of systemic complement inhibition.
ADX-097 is a tissue-targeted complement inhibitor, completed dosing healthy volunteers in its Phase 1, first-in-human study.